Is Genelink Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Genelink Inc (GNLKQ) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Genelink Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Genelink Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Genelink Inc?

Muslim investors may consider investing in Genelink Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Genelink Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Genelink Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Genelink Inc updated?

The Shariah compliance status of Genelink Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Genelink Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Genelink Inc?

You can check the latest Shariah compliance status of Genelink Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Genelink Inc. Stock Analysis GNLKQ

United States Health Care Nano Cap

GeneLink, Inc. is engaged in the development of genetics-based assessment products for pharmaceutical applications and DNA storage purpose. The company is headquartered in Elmsford, New York. The company went IPO on 2000-03-09. The firm offers a range of commercially available modifications, fluorescently labeled probes, and specialized probes, such as Molecular Beacons, TaqMan, and Fluorescence resonance energy transfer (FRET), as well as a variety of other molecular biology products, such as linkers, adaptors, deoxyribonucleic acid (DNA) purification and clean-up kits. The Company’s product line of gene detection systems comprises reagents and reagent systems for scientists in the detection of genetic disorders. The firm focuses on triple repeat disorders, which include fragile x, myotonic dystrophy, huntington's disease. The company also specializes in the synthesis of ribonucleic acid (RNA) modified oligos, RNA fluorescent probes with quenchers, chimeric oligos containing various combinations of DNA, 2'O methyl or chimerics. The firm serves various industries, including research institutes, pharmaceutical companies and hospitals.

Key Statistics of Genelink Inc (GNLKQ)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

500.00

P/E Ratio (TTM)

52 Week Range

$0.00$0.00

Market Cap

10.00K

Avg. Volume

10.25K

Dividend Yield

Financial Metrics & Statements of Genelink Inc (GNLKQ)

FAQ's for Genelink Inc (GNLKQ)

According to Musaffa’s Shariah screening methodology, Genelink Inc (GNLKQ) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.